Literature DB >> 21734232

The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.

Anthony J Courey1, Jeffrey C Horowitz, Kevin K Kim, Timothy J Koh, Margaret L Novak, Natalya Subbotina, Mark Warnock, Bing Xue, Andrew K Cunningham, Yujing Lin, Monica P Goldklang, Richard H Simon, Daniel A Lawrence, Thomas H Sisson.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is increased in the lungs of patients with pulmonary fibrosis, and animal studies have shown that experimental manipulations of PAI-1 levels directly influence the extent of scarring that follows lung injury. PAI-1 has 2 known properties that could potentiate fibrosis, namely an antiprotease activity that inhibits the generation of plasmin, and a vitronectin-binding function that interferes with cell adhesion to this extracellular matrix protein. To determine the relative importance of each PAI-1 function in lung fibrogenesis, we administered mutant PAI-1 proteins that possessed either intact antiprotease or vitronectin-binding activity to bleomycin-injured mice genetically deficient in PAI-1. We found that the vitronectin-binding capacity of PAI-1 was the primary determinant required for its ability to exacerbate lung scarring induced by intratracheal bleomycin administration. The critical role of the vitronectin-binding function of PAI-1 in fibrosis was confirmed in the bleomycin model using mice genetically modified to express the mutant PAI-1 proteins. We conclude that the vitronectin-binding function of PAI-1 is necessary and sufficient in its ability to exacerbate fibrotic processes in the lung.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734232      PMCID: PMC3162358          DOI: 10.1182/blood-2010-12-324574

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1.

Authors:  S Stefansson; E Petitclerc; M K Wong; G A McMahon; P C Brooks; D A Lawrence
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

2.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 3.  Development of pulmonary fibrosis in fibrinogen-deficient mice.

Authors:  J A Wilberding; V A Ploplis; L McLennan; Z Liang; I Cornelissen; M Feldman; M E Deford; E D Rosen; F J Castellino
Journal:  Ann N Y Acad Sci       Date:  2001       Impact factor: 5.691

Review 4.  Plasmin and matrix metalloproteinases in vascular remodeling.

Authors:  H R Lijnen
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

5.  The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.

Authors:  C M Swaisgood; E L French; C Noga; R H Simon; V A Ploplis
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  Pericellular plasmin induces smooth muscle cell anoikis.

Authors:  Olivier Meilhac; Benoît Ho-Tin-Noé; Xavier Houard; Monique Philippe; Jean-Baptiste Michel; Eduardo Anglés-Cano
Journal:  FASEB J       Date:  2003-05-08       Impact factor: 5.191

7.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Authors:  Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Radiological versus histological diagnosis in UIP and NSIP: survival implications.

Authors:  K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

9.  The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.

Authors:  Noboru Hattori; Shinya Mizuno; Yuka Yoshida; Kazuo Chin; Michiaki Mishima; Thomas H Sisson; Richard H Simon; Toshikazu Nakamura; Masayuki Miyake
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins.

Authors:  A K Scaffidi; Y P Moodley; M Weichselbaum; P J Thompson; D A Knight
Journal:  J Cell Sci       Date:  2001-10       Impact factor: 5.285

View more
  33 in total

1.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

2.  The vitronectin RGD motif regulates TGF-β-induced alveolar epithelial cell apoptosis.

Authors:  Amanda K Wheaton; Miranda Velikoff; Manisha Agarwal; Tiffany T Loo; Jeffrey C Horowitz; Thomas H Sisson; Kevin K Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-04-22       Impact factor: 5.464

3.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

4.  Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis.

Authors:  Jeffrey C Horowitz; Daniel J Tschumperlin; Kevin K Kim; John J Osterholzer; Natalya Subbotina; Iyabode O Ajayi; Seagal Teitz-Tennenbaum; Ammara Virk; Megan Dotson; Fei Liu; Delphine Sicard; Shijing Jia; Thomas H Sisson
Journal:  Thromb Haemost       Date:  2019-11-08       Impact factor: 5.249

5.  PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury.

Authors:  John J Osterholzer; Paul J Christensen; Vibha Lama; Jeffrey C Horowitz; Noboru Hattori; Natalya Subbotina; Andrew Cunningham; Yujing Lin; Benjamin J Murdock; Roger E Morey; Michal A Olszewski; Daniel A Lawrence; Richard H Simon; Thomas H Sisson
Journal:  J Pathol       Date:  2012-06-06       Impact factor: 7.996

6.  Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis.

Authors:  Thomas H Sisson; Iyabode O Ajayi; Natalya Subbotina; Amos E Dodi; Eva S Rodansky; Lauren N Chibucos; Kevin K Kim; Venkateshwar G Keshamouni; Eric S White; Yong Zhou; Peter D R Higgins; Scott D Larsen; Richard R Neubig; Jeffrey C Horowitz
Journal:  Am J Pathol       Date:  2015-02-11       Impact factor: 4.307

7.  Soy biodiesel and petrodiesel emissions differ in size, chemical composition and stimulation of inflammatory responses in cells and animals.

Authors:  Naomi K Fukagawa; Muyao Li; Matthew E Poynter; Brian C Palmer; Erin Parker; John Kasumba; Britt A Holmén
Journal:  Environ Sci Technol       Date:  2013-10-10       Impact factor: 9.028

8.  Ultrasound Strain Measurements for Evaluating Local Pulmonary Ventilation.

Authors:  Jonathan M Rubin; Jeffrey C Horowitz; Thomas H Sisson; Kang Kim; Luis A Ortiz; James D Hamilton
Journal:  Ultrasound Med Biol       Date:  2016-08-10       Impact factor: 2.998

9.  Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.

Authors:  Payal K Naik; Paul D Bozyk; J Kelley Bentley; Antonia P Popova; Carolyn M Birch; Carol A Wilke; Christopher D Fry; Eric S White; Thomas H Sisson; Nabihah Tayob; Barbara Carnemolla; Paola Orecchia; Kevin R Flaherty; Marc B Hershenson; Susan Murray; Fernando J Martinez; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-10-05       Impact factor: 5.464

10.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.